U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H12ClF3N2O
Molecular Weight 352.738
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HALAZEPAM

SMILES

FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3

InChI

InChIKey=WYCLKVQLVUQKNZ-UHFFFAOYSA-N
InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2

HIDE SMILES / InChI

Molecular Formula C17H12ClF3N2O
Molecular Weight 352.738
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.wikidoc.org/index.php/Halazepam | http://www.pharmacychoice.com/mdx/drugpoint.cfm?docID=268590&letter=P&type=Trade%20Name&tradeName=Paxipam

Halazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Halazepam is used to relieve anxiety, nervousness, and tension associated with anxiety disorders. Halazepam (Paxipam) is no longer commercially available in the United States. Common adverse effects are: hypotension, nausea, xerostomia, confusion, headache. Alcohol should be avoided while taking Paxipam as it causes drowsiness as well. Medications that also cause drowsiness should not be taken along with Paxipam. These include: Antidepressants, Pain relievers, Seizure medications, Muscle relaxants, Antihistamines, Sleeping pills and sedatives.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PAXIPAM

Approved Use

Halazepam is used to relieve anxiety, nervousness, and tension associated with anxiety disorders.

Launch Date

1981
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
916 ng/mL
40 mg 3 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NORDAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
147 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORDAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
93 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HALAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
137 ng/mL
40 mg 3 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
HALAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5863 ng × h/mL
40 mg 3 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NORDAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
796 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORDAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
347 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HALAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
640 ng × h/mL
40 mg 3 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
HALAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.9 h
40 mg 3 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
HALAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.
2005 Dec
[Consumption of inappropriate psychotropic drugs in residential homes for the elderly: comparative study between 2001 and 2006].
2008 Mar-Apr
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Patents

Patents

Sample Use Guides

20-40 mg 3-4 times a day; optimal doses range from 80-160 mg/day
Route of Administration: Oral
In Vitro Use Guide
Competition curves generated by displacing [3H]-flunitrazepam binding, in sections of the forebrain, with halazepam showed IC50 values of 124.45 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:10 GMT 2023
Edited
by admin
on Fri Dec 15 15:10:10 GMT 2023
Record UNII
320YC168LF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HALAZEPAM
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
SCH-12041
Code English
HALAZEPAM [VANDF]
Common Name English
HALAZEPAM [ORANGE BOOK]
Common Name English
PAXIPAM
Brand Name English
SCH 12041
Code English
7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one
Systematic Name English
HALAZEPAM [USAN]
Common Name English
HALAZEPAM CIV
USP-RS  
Common Name English
Halazepam [WHO-DD]
Common Name English
HALAZEPAM [MI]
Common Name English
2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1,3-DIHYDRO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)-
Systematic Name English
HALAZEPAM [MART.]
Common Name English
halazepam [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1012
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
WHO-VATC QN05BA13
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
WHO-ATC N05BA13
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
DEA NO. 2762
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
Code System Code Type Description
WIKIPEDIA
HALAZEPAM
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
RXCUI
26412
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL970
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID5023118
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
DRUG CENTRAL
1348
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
ECHA (EC/EINECS)
245-425-4
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
MESH
C010175
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
EVMPD
SUB07992MIG
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
DRUG BANK
DB00801
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
IUPHAR
7195
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
MERCK INDEX
m5894
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY Merck Index
INN
3339
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
FDA UNII
320YC168LF
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
CAS
23092-17-3
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
NCI_THESAURUS
C61780
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
PUBCHEM
31640
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
SMS_ID
100000084477
Created by admin on Fri Dec 15 15:10:10 GMT 2023 , Edited by admin on Fri Dec 15 15:10:10 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY